Adjusted HRs (95% CIs) comparing the safety and effectiveness of oral anticoagulant users to matched warfarin users for the treatment of nonvalvular AF in active cancer patients, MarketScan, 2010-2014
| . | No. of events . | Person-years . | No. of events . | Person-years . | HR (95% CI) . | P . |
|---|---|---|---|---|---|---|
| Rivaroxaban user (n = 2808) | Matched warfarin user (n = 5673) | |||||
| Ischemic stroke | 16 | 2277 | 59 | 5 279 | 0.74 (0.40, 1.39) | .35 |
| Severe bleeding | 68 | 2245 | 181 | 5 207 | 1.09 (0.79, 1.50) | .59 |
| Other bleeding | 50 | 2213 | 177 | 5 031 | 0.79 (0.55, 1.13) | .2 |
| VTE* | 124 | 2046 | 472 | 3 903 | 0.51 (0.41, 0.63) | <.0001 |
| Asthma (control outcome) | 41 | 2259 | 91 | 5 253 | 0.99 (0.64, 1.51) | .94 |
| Dabigatran user (n = 2189) | Matched warfarin user (n = 8339) | |||||
| Ischemic stroke | 26 | 3310 | 127 | 10 878 | 0.89 (0.56, 1.42) | .63 |
| Severe bleeding | 70 | 3273 | 329 | 10 706 | 0.96 (0.72, 1.27) | .75 |
| Other bleeding | 40 | 3236 | 306 | 10 376 | 0.58 (0.41, 0.84) | .003 |
| VTE* | 49 | 3199 | 743 | 8 206 | 0.28 (0.21, 0.38) | <.0001 |
| Asthma (control outcome) | 38 | 3302 | 183 | 10 825 | 0.75 (0.51, 1.10) | .14 |
| Apixaban user (n = 1078) | Matched warfarin user (n = 2775) | |||||
| Ischemic stroke | 4 | 550 | 18 | 1 773 | 0.71 (0.19, 2.60) | .6 |
| Severe bleeding | 10 | 551 | 84 | 1 744 | 0.37 (0.17, 0.79) | .01 |
| Other bleeding | 9 | 538 | 72 | 1 699 | 0.58 (0.25, 1.31) | .19 |
| VTE* | 7 | 540 | 218 | 1 325 | 0.14 (0.07, 0.32) | <.0001 |
| Asthma (control outcome) | 13 | 549 | 40 | 1 760 | 0.99 (0.53, 2.22) | .98 |
| . | No. of events . | Person-years . | No. of events . | Person-years . | HR (95% CI) . | P . |
|---|---|---|---|---|---|---|
| Rivaroxaban user (n = 2808) | Matched warfarin user (n = 5673) | |||||
| Ischemic stroke | 16 | 2277 | 59 | 5 279 | 0.74 (0.40, 1.39) | .35 |
| Severe bleeding | 68 | 2245 | 181 | 5 207 | 1.09 (0.79, 1.50) | .59 |
| Other bleeding | 50 | 2213 | 177 | 5 031 | 0.79 (0.55, 1.13) | .2 |
| VTE* | 124 | 2046 | 472 | 3 903 | 0.51 (0.41, 0.63) | <.0001 |
| Asthma (control outcome) | 41 | 2259 | 91 | 5 253 | 0.99 (0.64, 1.51) | .94 |
| Dabigatran user (n = 2189) | Matched warfarin user (n = 8339) | |||||
| Ischemic stroke | 26 | 3310 | 127 | 10 878 | 0.89 (0.56, 1.42) | .63 |
| Severe bleeding | 70 | 3273 | 329 | 10 706 | 0.96 (0.72, 1.27) | .75 |
| Other bleeding | 40 | 3236 | 306 | 10 376 | 0.58 (0.41, 0.84) | .003 |
| VTE* | 49 | 3199 | 743 | 8 206 | 0.28 (0.21, 0.38) | <.0001 |
| Asthma (control outcome) | 38 | 3302 | 183 | 10 825 | 0.75 (0.51, 1.10) | .14 |
| Apixaban user (n = 1078) | Matched warfarin user (n = 2775) | |||||
| Ischemic stroke | 4 | 550 | 18 | 1 773 | 0.71 (0.19, 2.60) | .6 |
| Severe bleeding | 10 | 551 | 84 | 1 744 | 0.37 (0.17, 0.79) | .01 |
| Other bleeding | 9 | 538 | 72 | 1 699 | 0.58 (0.25, 1.31) | .19 |
| VTE* | 7 | 540 | 218 | 1 325 | 0.14 (0.07, 0.32) | <.0001 |
| Asthma (control outcome) | 13 | 549 | 40 | 1 760 | 0.99 (0.53, 2.22) | .98 |
Adjusted for age, sex, CHA2DS2-VASc score, prior history of the outcome, and HDPS.
Patients with prevalent VTE excluded from the analysis.